Reporter gene imaging of immune responses to cancer: Progress and challenges

Theranostics

Volumn 2, Issue 4, 2012, Pages 355-362

  Dubey, Purnima ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Immune responses; Reporter gene imaging

Indexed keywords

LENTIVIRUS VECTOR; RADIOISOTOPE; RETROVIRUS VECTOR;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; BIOLOGICAL MONITORING; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MOTION; CELL POPULATION; CELL TYPE; DENDRITIC CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; ISOTOPE LABELING; MACROPHAGE; MOLECULAR IMAGING; NEUTROPHIL; NONHUMAN; REGULATORY T LYMPHOCYTE; REPORTER GENE; REVIEW; T LYMPHOCYTE;

EID: 84864539377     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3903     Document Type: Review

References (62)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: inte-grating immunity's roles in cancer suppression and promotion. Science. 2011; 331: 1565-70.
2. Shanker A, Marincola FM. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother. 2011; 60: 1061-74.
3. Gross S, Moss BL, Piwnica-Worms D. Veni, vidi, vici: in vivo molecular imaging of immune response. Immunity. 2007; 27: 533-8.
4. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003; 17: 545-80.
5. Akins EJ, Dubey P. Noninvasive imaging of cell-mediated therapy for treatment of cancer. J Nucl Med. 2008; 49 Suppl 2: 180S-95S.
6. Ottobrini L, Martelli C, Trabattoni DL, Clerici M, Lucignani G. In vivo imaging of immune cell trafficking in cancer. Eur J Nucl Med Mol Imaging. 2011; 38: 949-68.
7. Celli S, Bousso P. Intravital two-photon imaging of T-cell priming and tolerance in the lymph node. Methods Mol Biol. 2007; 380: 355-63.
8. Sumen C, Mempel TR, Mazo IB, von Andrian UH. Intravital microscopy: visualizing immunity in context. Immunity. 2004; 21: 315-29.
9. Galban CJ, Galban S, Van Dort ME, Luker GD, Bhojani MS, Rehemtulla A, et al. Applications of molecular imaging. Prog Mol Biol Transl Sci. 2010; 95: 237-98.
10. Kang JH, Chung JK. Molecular-genetic imaging based on re-porter gene expression. J Nucl Med. 2008; 49 Suppl 2: 164S-79S.
11. Ray P. The pivotal role of multimodality reporter sensors in drug discovery: from cell based assays to real time molecular imaging. Curr Pharm Biotechnol. 2011; 12: 539-46.
12. Greer LF, 3rd, Szalay AA. Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence. 2002; 17: 43-74.
13. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A. 2008; 105: 14342-6.
14. Loening AM, Fenn TD, Wu AM, Gambhir SS. Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng Des Sel. 2006; 19: 391-400.
15. Chung E, Yamashita H, Au P, Tannous BA, Fukumura D, Jain RK. Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS One. 2009; 4: e8316.
16. Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, La Perle K, et al. Sensitive in vivo imaging of T cells using a mem-rane-bound Gaussia princeps luciferase. Nat Med. 2009; 15: 338-44.
17. Brust P, Haubner R, Friedrich A, Scheunemann M, Anton M, Koufaki ON, et al. Comparison of [18F]FHPG and [124/125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. Eur J Nucl Med. 2001; 28: 721-9.
18. Campbell DO, Yaghoubi S, Su Y, Lee JT, Auerbach MS, Herschman H, et al. Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of a non-natural thymidine analog reporter probe. J Biol Chem. 2012.
19. Ponomarev V, Doubrovin M, Shavrin A, Serganova I, Beresten T, Ageyeva L, et al. A human-derived reporter gene for noninvasive imaging in humans: mitochondrial thymidine kinase type 2. J Nucl Med. 2007; 48: 819-26.
20. Kesarwala AH, Prior JL, Sun J, Harpstrite SE, Sharma V, Piwnica-Worms D. Second-generation triple reporter for bioluminescence, micro-positron emission tomography, and fluorescence imaging. Mol Imaging. 2006; 5: 465-74.
21. Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging. 2004; 31: 740-51.
22. Ray P, Tsien R, Gambhir SS. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res. 2007; 67: 3085-93.
23. Chinnasamy N, Shaffer J, Chinnasamy D. Production of multicistronic HIV-1 based lentiviral vectors. Methods Mol Biol. 2009; 515: 137-50.
24. Azadniv M, Dugger K, Bowers WJ, Weaver C, Crispe IN. Imaging CD8+ T cell dynamics in vivo using a transgenic luciferase reporter. Int Immunol. 2007; 19: 1165-73.
25. Chewning JH, Dugger KJ, Chaudhuri TR, Zinn KR, Weaver CT. Bioluminescence-based visualization of CD4 T cell dynamics using a T lineage-specific luciferase transgenic model. BMC Immunol. 2009; 10: 44.
26. Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res. 2011; 71: 6915-20.
27. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol Res. 2010; 46: 79-93.
28. Jeremiah NM, Liston A. Genetic tools for analysis of FoxP3+ regulatory T cells in vivo. Methods Mol Biol. 2011; 707: 105-18.
29. Hume DA. Applications of myeloid-specific promoters in transgenic mice support in vivo imaging and functional genomics but do not support the concept of distinct macrophage and dendritic cell lineages or roles in immunity. J Leukoc Biol. 2011; 89: 525-38.
30. Creusot RJ, Yaghoubi SS, Chang P, Chia J, Contag CH, Gambhir SS, et al. Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells. Blood. 2009; 113: 6638-47.
31. Tanaka M, Swijnenburg RJ, Gunawan F, Cao YA, Yang Y, Caffarelli AD, et al. In vivo visualization of cardiac allograft rejection and trafficking passenger leukocytes using bioluminescence imaging. Circulation. 2005; 112: I105-10.
32. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev. 2011; 239: 27-44.
33. Cao YA, Wagers AJ, Beilhack A, Dusich J, Bachmann MH, Negrin RS, et al. Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci U S A. 2004; 101: 221-6.
34. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003; 101: 640-8.
35. Na IK, Markley JC, Tsai JJ, Yim NL, Beattie BJ, Klose AD, et al. Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. Blood. 2010; 116: e18-25.
36. Schimmelpfennig CH, Schulz S, Arber C, Baker J, Tarner I, McBride J, et al. Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation. Am J Pathol. 2005; 167: 1321-31.
37. Dubey P, Su H, Adonai N, Du S, Rosato A, Braun J, et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci U S A. 2003; 100: 1232-7.
38. Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 2003; 21: 405-13.
39. Marodon G, Mouly E, Blair EJ, Frisen C, Lemoine FM, Klatzmann D. Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood. 2003; 101: 3416-23.
40. Mouly E, Dorival C, Pflumio F, Baillou C, Coulombel L, Levy Y, et al. CD4 regulation in human lymphoid non-T-cells: a role for the silencer element. Mol Immunol. 2007; 44: 267-75.
41. Pipkin ME, Ljutic B, Cruz-Guilloty F, Nouzova M, Rao A, Zuniga-Pflucker JC, et al. Chromosome transfer activates and delineates a locus control region for perforin. Immunity. 2007; 26: 29-41.
42. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003; 348: 255-6.
43. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003; 302: 415-9.
44. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008; 118: 3143-50.
45. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996; 2: 216-23.
46. Rosenzweig M, Connole M, Glickman R, Yue SP, Noren B, DeMaria M, et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood. 2001; 97: 1951-9.
47. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 1999; 6: 1305-12.
48. Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007; 109: 4708-15.
49. Shu CJ, Guo S, Kim YJ, Shelly SM, Nijagal A, Ray P, et al. Visu-alization of a primary antitumor immune response by positron emission tomography. Proc Natl Acad Sci U S A. 2005; 102: 17412-7.
50. Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol. 2005; 130: 809-24.
51. Crabtree GR. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell. 1999; 96: 611-4.
52. Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, et al. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia. 2001; 3: 480-8.
53. Saibil SD, Deenick EK, Ohashi PS. The sound of silence: modulating anergy in T lymphocytes. Curr Opin Immunol. 2007; 19: 658-64.
54. Patel MR, Chang YF, Chen IY, Bachmann MH, Yan X, Contag CH, et al. Longitudinal, noninvasive imaging of T-cell effector function and proliferation in living subjects. Cancer Res. 2011; 70: 10141-9.
55. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8: 299-308.
56. Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med. 2008; 49: 1162-70.
57. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005; 65: 9080-8.
58. Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, et al. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A. 2010; 107: 14286-91.
59. Roszik J, Rabinovich B, Cooper LJ. Imaging of T cells expressing chimeric antigen receptors. Immunotherapy. 2011; 3: 1411-4. doi:10.2217/imt.11.138.
60. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, et al. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol. 2009; 6: 53-8.
61. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2′-deoxycytidine analog. Nat Med. 2008; 14: 783-8.
62. Namavari M, Chang YF, Kusler B, Yaghoubi S, Mitchell BS, Gambhir SS. Synthesis of 2′-deoxy-2′-[18F]fluoro-9-beta-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET. Mol Imaging Biol. 2011; 13: 812-8.